NVAX s Covid Jab Shows 89.3% Efficacy In UK Trial, AZRX Awaits Data, FDA Lifts Hold On BLCM Trial
Read on.
1. Will Ayala Pharma s Tenacity Pay Off?
Ayala Pharmaceuticals Inc. (AYLA) has dosed the first patient in its phase II clinical trial of AL101 for the treatment of patients with Notch-activated recurrent or metastatic (R/M) triple negative breast cancer.
The trial, dubbed TENACITY, is expected to initially enroll up to 26 patients with Notch-activated R/M TNBC whose disease has recurred or progressed after three or fewer lines of prior therapy. The preliminary data from the trial is expected to be reported by the end of 2021.